Genedata Announces Evotec Selects Genedata Screener
News Jun 29, 2016
Genedata has announced that Evotec has selected Genedata Screener® as a data management platform solution for its drug discovery projects. Originally deployed for High Content Screening (HCS), Evotec now also licenses Genedata Screener for its High Throughput Screening (HTS) operations. This capability further strengthens Evotec's support of drug discovery research projects with global pharmaceutical, biotechnology, and academic partners.
Leading CROs and More than 50% of the World's Top Pharmas Run Genedata Screener Genedata Screener is relied on by many innovative contract research organizations (CROs) and is used by more than 50% of the world's leading pharmaceutical companies. It enables CROs to efficiently serve their customers with quick yet thorough data analysis, ensuring scientists deliver well-curated results.
While Evotec uses Screener for HCS and HTS, the platform also supports a broad range of modern screening technologies including: Surface Plasmon Resonance; Thermal Shift Analysis; Compound Combinations; HT-Flow; Ion Channel; and Profiling. "Genedata Screener is one of the standard screening platforms for many of our pharmaceutical customers," said Dr. Dirk Ullmann, EVP Lead Discovery of Evotec.
"Standardizing result generation and quality control, Screener is key to our customer collaborations because it allows everyone to quickly understand the results and result quality. It enables our scientists to deliver results quickly and easily to our customers."
One Platform for Full HTS and HCS Analysis
Genedata Screener for both HCS and HTS provides stringent quality assurance, transparent hit identification, and interactively curates any process errors. It enables scientists to easily understand what causes artifacts or quickly identify new phenotypes. And, it can quickly pull original HCS images, dozens out of millions, in a full HCS campaign. These efficiencies are further complemented by the Genedata Screener infrastructure, which reduces costs and maintenance as it hosts full HTS and HCS data analysis in one system, scales to all throughputs, and adapts to widely-used assay formats.
"Genedata Screener has become the software of choice for screening data analysis in pharma and bio-pharma industries," noted Dr. Othmar Pfannes, CEO of Genedata. "Therefore, we're seeing increased Screener adoption by leading CROs, such as Evotec, who see quantifiable value in using the same data analysis methodology used by their customers. Genedata is committed to increasing that value by investing in our software so that it continually keeps pace with new business concepts, technologies and workflows as they arise."
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
High-throughput Screening: Microscale Thermophoresis to Characterize HitsNews
A new perspective article details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018